Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.


Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 06 04 2021
accepted: 13 07 2021
pubmed: 26 7 2021
medline: 28 10 2021
entrez: 25 7 2021
Statut: ppublish

Résumé

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease. Its etiology remains largely unknown, although frequent concomitant inflammatory bowel disease (IBD) hints towards common factors underlying intestinal and bile duct inflammation. Herein, we aimed to explore the relative abundance of fecal microbiota in PSC-IBD patients compared to IBD-only subjects and controls. We included 14 PSC-IBD patients, 12 IBD-only patients, and 8 healthy controls (HCs). A quantitative real-time PCR (qPCR) assay was used to determine a selection of bacterial phyla, families, and genera. Relative abundance of taxa showed that Bacteroidetes was the most abundant phylum among the patients with PSC-IBD (29.46%) and also HCs (39.34%), whereas the bacterial species belonging to the phylum Firmicutes were the most frequent group in IBD-only subjects (37.61%). The relative abundance of the Enterobacteriaceae family in fecal samples of PSC-IBD patients was similar to those with IBD-only, which was significantly higher than HCs (p value = 0.031), and thus, could be used as a PSC-IBD or IBD-only associated microbial signature. Our findings showed that intestinal microbiota composition in PSC-IBD patients was completely different from that of IBD-only patients. Further studies using large-scale cohorts should be performed to better describe the contribution of the gut microbiota to PSC pathogenesis with underlying IBD.

Sections du résumé

BACKGROUND BACKGROUND
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease. Its etiology remains largely unknown, although frequent concomitant inflammatory bowel disease (IBD) hints towards common factors underlying intestinal and bile duct inflammation. Herein, we aimed to explore the relative abundance of fecal microbiota in PSC-IBD patients compared to IBD-only subjects and controls.
METHODS AND RESULTS RESULTS
We included 14 PSC-IBD patients, 12 IBD-only patients, and 8 healthy controls (HCs). A quantitative real-time PCR (qPCR) assay was used to determine a selection of bacterial phyla, families, and genera. Relative abundance of taxa showed that Bacteroidetes was the most abundant phylum among the patients with PSC-IBD (29.46%) and also HCs (39.34%), whereas the bacterial species belonging to the phylum Firmicutes were the most frequent group in IBD-only subjects (37.61%). The relative abundance of the Enterobacteriaceae family in fecal samples of PSC-IBD patients was similar to those with IBD-only, which was significantly higher than HCs (p value = 0.031), and thus, could be used as a PSC-IBD or IBD-only associated microbial signature.
CONCLUSIONS CONCLUSIONS
Our findings showed that intestinal microbiota composition in PSC-IBD patients was completely different from that of IBD-only patients. Further studies using large-scale cohorts should be performed to better describe the contribution of the gut microbiota to PSC pathogenesis with underlying IBD.

Identifiants

pubmed: 34304365
doi: 10.1007/s11033-021-06567-8
pii: 10.1007/s11033-021-06567-8
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5519-5529

Subventions

Organisme : Shahid Beheshti University of Medical Sciences
ID : 930

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Hirschfield GM, Karlsen TH, Lindor KD, Adams DH (2013) Primary sclerosing cholangitis. Lancet (London, England) 382(9904):1587–1599
doi: 10.1016/S0140-6736(13)60096-3
de Vries EM, Wang J, Williamson KD, Leeflang MM, Boonstra K, Weersma RK, Beuers U, Chapman RW, Geskus RB, Ponsioen CY (2018) A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut 67(10):1864–1869
pubmed: 28739581 doi: 10.1136/gutjnl-2016-313681
Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (Baltimore, MD) 58(6):2045–2055
doi: 10.1002/hep.26565
Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD (2013) Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 145(3):521–536
pubmed: 23827861 doi: 10.1053/j.gastro.2013.06.052
Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P, Ryden BO, Tysk C, Wallerstedt S (1991) Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 100(5 Pt 1):1319–1323
pubmed: 2013375 doi: 10.1016/0016-5085(91)70019-T
Boonstra K, Beuers U, Ponsioen CY (2012) Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 56(5):1181–1188
pubmed: 22245904 doi: 10.1016/j.jhep.2011.10.025
O’Toole A, Alakkari A, Keegan D, Doherty G, Mulcahy H, O’Donoghue D (2012) Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol 10(4):439–441
pubmed: 22094024 doi: 10.1016/j.cgh.2011.11.010
Boonstra K, van Erpecum KJ, van Nieuwkerk KM, Drenth JP, Poen AC, Witteman BJ, Tuynman HA, Beuers U, Ponsioen CY (2012) Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 18(12):2270–2276
pubmed: 22407885 doi: 10.1002/ibd.22938
Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B et al (2013) Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 45(6):670–675
pubmed: 23603763 pmcid: 3667736 doi: 10.1038/ng.2616
Kevans D, Tyler AD, Holm K, Jorgensen KK, Vatn MH, Karlsen TH, Kaplan GG, Eksteen B, Gevers D, Hov JR et al (2016) Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 10(3):330–337
pubmed: 26526357 doi: 10.1093/ecco-jcc/jjv204
Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB (1991) Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology (Baltimore, MD) 13(4):766–772
doi: 10.1002/hep.1840130425
Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD (2013) Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis—a pilot study. Aliment Pharmacol Ther 37(6):604–612
pubmed: 23384404 doi: 10.1111/apt.12232
Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Karkkainen P (2004) Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology (Baltimore, MD) 40(6):1379–1386
doi: 10.1002/hep.20457
Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology (Baltimore, MD) 51(2):660–678
doi: 10.1002/hep.23294
Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol 170:2–6; discussion 16–19
Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, LaRusso NF, Lindor KD, Dickson ER (2000) A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75(7):688–694
pubmed: 10907383 doi: 10.1016/S0025-6196(11)64614-4
Bacchetti De Gregoris T, Aldred N, Clare AS, Burgess JG (2011) Improvement of phylum- and class-specific primers for real-time PCR quantification of bacterial taxa. J Microbiol Methods 86(3):351–356
pubmed: 21704084 doi: 10.1016/j.mimet.2011.06.010
Kummen M, Holm K, Anmarkrud JA, Nygård S, Vesterhus M, Høivik ML, Trøseid M, Marschall HU, Schrumpf E, Moum B et al (2017) The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66(4):611–619
pubmed: 26887816 doi: 10.1136/gutjnl-2015-310500
Rossen NG, Fuentes S, Boonstra K, D’Haens GR, Heilig HG, Zoetendal EG, de Vos WM, Ponsioen CY (2015) The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 9(4):342–348
pubmed: 25547975 doi: 10.1093/ecco-jcc/jju023
Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, Ferrante M, Van Assche G, Van der Merwe S, Vermeire S et al (2016) Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65(10):1681–1689
pubmed: 27207975 doi: 10.1136/gutjnl-2015-311004
Kolde R, Franzosa EA, Rahnavard G, Hall AB, Vlamakis H, Stevens C, Daly MJ, Xavier RJ, Huttenhower C (2018) Host genetic variation and its microbiome interactions within the Human Microbiome Project. Genome Med 10(1):6–6
pubmed: 29378630 pmcid: 5789541 doi: 10.1186/s13073-018-0515-8
Gupta VK, Paul S, Dutta C (2017) Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol 8:1162
pubmed: 28690602 pmcid: 5481955 doi: 10.3389/fmicb.2017.01162
Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N et al (2019) Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 4(3):492–503
pubmed: 30643240 doi: 10.1038/s41564-018-0333-1
Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q, Yang F, Miao Q, Xiao X, Zhang H et al (2018) Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67(3):534–541
pubmed: 28213609 doi: 10.1136/gutjnl-2016-313332
Steffen EK, Berg RD, Deitch EA (1988) Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis 157(5):1032–1038
pubmed: 3283254 doi: 10.1093/infdis/157.5.1032
Jackaman FR, Hilson GR, Smith L (1980) Bile bacteria in patients with benign bile duct stricture. Br J Surg 67(5):329–332
pubmed: 7388326 doi: 10.1002/bjs.1800670509
Maddocks AC, Hilson GR, Taylor R (1973) The bacteriology of the obstructed biliary tree. Ann R Coll Surg Engl 52(5):316–319
pubmed: 4576766 pmcid: 2388236
Rerknimitr R, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S (2002) Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc 56(6):885–889
pubmed: 12447303 doi: 10.1016/S0016-5107(02)70365-9
Pohl J, Ring A, Stremmel W, Stiehl A (2006) The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 18(1):69–74
pubmed: 16357622 doi: 10.1097/00042737-200601000-00012
Nadalian B, Yadegar A, Houri H, Olfatifar M, Shahrokh S, Asadzadeh Aghdaei H, Suzuki H, Zali MR (2021) Prevalence of the pathobiont adherent-invasive Escherichia coli and inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 36(4):852–863
pubmed: 32929762 doi: 10.1111/jgh.15260
Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K et al (2014) A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63(8):1275–1283
doi: 10.1136/gutjnl-2013-304833 pubmed: 24021287
Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A (2020) Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroenterol 26(21):2768–2780
pubmed: 32550753 pmcid: 7284173 doi: 10.3748/wjg.v26.i21.2768
Kabeerdoss J, Jayakanthan P, Pugazhendhi S, Ramakrishna BS (2015) Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res 142(1):23–32
pubmed: 26261163 pmcid: 4557246 doi: 10.4103/0971-5916.162091
Sokol H, Seksik P, Furet J, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15(8):1183–1189
pubmed: 19235886 doi: 10.1002/ibd.20903
Hirschfield GM, Karlsen TH, Lindor KD, Adams DH (2013) Primary sclerosing cholangitis. Lancet 382(9904):1587–1599
pubmed: 23810223 doi: 10.1016/S0140-6736(13)60096-3
de Moraes JG, Motta MEFA, Beltrão MFS, Salviano TL, da Silva GAP (2016) Fecal microbiota and diet of children with chronic constipation. Int J Pediatr 2016:6787269–6787269
pubmed: 27418934 pmcid: 4935906 doi: 10.1155/2016/6787269
Yang YW, Chen MK, Yang BY, Huang XJ, Zhang XR, He LQ, Zhang J, Hua ZC (2015) Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in mouse feces. Appl Environ Microbiol 81(19):6749–6756
pubmed: 26187967 pmcid: 4561689 doi: 10.1128/AEM.01906-15
Hermann-Bank ML, Skovgaard K, Stockmarr A, Larsen N, Mølbak L (2013) The Gut Microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity. BMC Genomics 14:788
pubmed: 24225361 pmcid: 3879714 doi: 10.1186/1471-2164-14-788
Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, Tanaka R (2002) Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol 68(11):5445–5451
pubmed: 12406736 pmcid: 129894 doi: 10.1128/AEM.68.11.5445-5451.2002
Hung C-H, Cheng C-H, Cheng L-H, Liang C-M, Lin C-Y (2008) Application of Clostridium-specific PCR primers on the analysis of dark fermentation hydrogen-producing bacterial community. Int J Hydrogen Energy 33(5):1586–1592
doi: 10.1016/j.ijhydene.2007.09.037
Wang IK, Lai H-C, Yu C-J, Liang C-C, Chang C-T, Kuo H-L, Yang Y-F, Lin C-C, Lin H-H, Liu Y-L et al (2012) Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl Environ Microbiol 78(4):1107
pubmed: 22179250 pmcid: 3273023 doi: 10.1128/AEM.05605-11
Martineau F, Picard FJ, Ke D, Paradis S, Roy PH, Ouellette M, Bergeron MG (2001) Development of a PCR assay for identification of Staphylococci at genus and species levels. J Clin Microbiol 39(7):2541
pubmed: 11427566 pmcid: 88182 doi: 10.1128/JCM.39.7.2541-2547.2001

Auteurs

Samaneh Ostadmohammadi (S)

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Masoumeh Azimirad (M)

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hamidreza Houri (H)

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Kaveh Naseri (K)

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ehsan Javanmard (E)

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hamed Mirjalali (H)

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abbas Yadegar (A)

Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. a.yadegar@sbmu.ac.ir.

Amir Sadeghi (A)

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. amirsadeghimd@yahoo.com.

Hamid Asadzadeh Aghdaei (H)

Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mohammad Reza Zali (MR)

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH